MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2323
-0.0076
-3.17%
Opening 10:28 01/27 EST
OPEN
0.2582
PREV CLOSE
0.2399
HIGH
0.2582
LOW
0.2320
VOLUME
428.69K
TURNOVER
--
52 WEEK HIGH
3.790
52 WEEK LOW
0.2058
MARKET CAP
23.68M
P/E (TTM)
-0.4053
1D
5D
1M
3M
1Y
5Y
Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing
Abeona Therapeutics (ABEO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimate...
Zacks · 2d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 12/30/2021 13:07
BRIEF-Abeona Therapeutics Inc - Expect To Begin 2022 With Cash And Financial Resources Of More Than $50 Million (Unaudited)
reuters.com · 12/22/2021 12:42
Abeona Therapeutics Issues Letter To Shareholders
NEW YORK and CLEVELAND, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders.   Dear fellow
Benzinga · 12/22/2021 12:34
Abeona Therapeutics Issues Letter to Shareholders
NEW YORK and CLEVELAND, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders. Dear fellow shareholders, We have never been closer to...
GlobeNewswire · 12/22/2021 12:30
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.
Benzinga · 12/17/2021 17:03
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 12/17/2021 13:38
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Benzinga · 12/16/2021 23:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABEO. Analyze the recent business situations of Abeona through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ABEO stock price target is 3.000 with a high estimate of 4.000 and a low estimate of 1.000.
High4.000
Average3.000
Low1.000
Current 0.2500
EPS
Actual
Estimate
-0.15-0.11-0.08-0.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 122
Institutional Holdings: 35.17M
% Owned: 34.51%
Shares Outstanding: 101.92M
TypeInstitutionsShares
Increased
11
659.24K
New
6
720.37K
Decreased
20
2.06M
Sold Out
18
1.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chairman/Director
Michael Amoroso
President/Chief Executive Officer/Director
Vishwas Seshadri
Chief Financial Officer/Senior Vice President
Edward Carr
Senior Vice President/General Counsel
Brendan O Malley
Vice President
Brian Kevany
Director
Christine Silverstein
Independent Director
Leila Alland
Independent Director
Mark Alvino
Independent Director
Faith Charles
Independent Director
Paul Mann
Independent Director
Todd Wider
Independent Director
Donald Wuchterl
No Data
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). It is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.